 |
Charis Eng, M.D., Ph.D.Department ChairSondra J. and Stephen R. Hardis Chair of Cancer Genomic MedicineGenomic Medicine Institute (NE50) |
Secondary Appointments: Taussig Cancer Center
Academic Appointments: Professor and Vice Chairman, Department of Genetics, Case Western Reserve University School of Medicine
Professor, Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine
Honorary Appointments: Honorary Fellow, Cancer Research UK Human Cancer Genetics Research Group, University of Cambridge, Cambridge, UK
National Scholar, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus
Education and Training:
- BA, University of Chicago, IL
- PhD, University of Chicago, IL
- MD, University of Chicago, IL
- Internal Medicine Residency, Beth Israel Hospital, Boston
- Medical Oncology Fellowship, Dana-Farber Cancer Institute, Boston
- Clinical Cancer Genetics Fellowship, University of Cambridge Addenbrooke’s Hospital and Royal Marsden NHS Trust, London, UK
- Postdoctoral Fellowship, CRC Human Cancer Genetics Research Group, University of Cambridge, UK
Selected Major Honors and Awards:
- Elected Member, American Society for Clinical Investigation (ASCI)
- Doris Duke Distinguished Clinical Scientist Award
- Elected Fellow, American Association for the Advancement of Science (AAAS)
- Elected Member, Association of American Physicians (AAP)
- Local Legend from Ohio, bestowed by the American Medical Women’s Association in conjunction with the National Library of Medicine on women physicians who have demonstrated commitment, originality, innovation and/or creativity in their fields of medicine
- ATA Van Meter Award for Outstanding Research on the Thyroid Gland and Related Topics, 13th International Thyroid Congress, Buenos Aires, Argentina
- Ernst Oppenheimer Memorial Award for Outstanding Achievements in Endocrine Research, The Endocrine Society, Boston, MA
- The Endocrine Society / Pfizer, International Inc. Finalist Award for Excellence in Published Clinical Research in J Clin Endocrinol Metab in 2005, The Endocrine Society, Boston, MA
- American Cancer Society (Ohio Division) John Peter Minton, MD, PhD Hero of Hope Research Medal of Honor in recognition of significant contributions to the advancement of cancer research in Ohio
Narrative Biosketch:
Charis Eng, MD, PhD is the Chair and founding Director of the Genomic Medicine Institute of the Cleveland Clinic Foundation, founding Director and attending clinical cancer geneticist of the institute’s clinical component, the Center for Personalized Genetic Healthcare, and Professor and Vice Chairman of the Department of Genetics at Case Western Reserve University School of Medicine. She holds a joint appointment as Professor of Molecular Medicine at the Cleveland Clinic Lerner College of Medicine and is a member of Cleveland Clinic’s Taussig Cancer Center as well as the CASE Comprehensive Cancer Center. She was recently honored by the designation National Scholar of the Davis Heart and Lung Research Institute of The Ohio State University, and continues to hold an honorary appointment at the University of Cambridge. Dr. Eng’s research interests may be broadly characterized as cancer genomic medicine translational research. Her work on RET testing in multiple endocrine neoplasia type 2 and the characterization of the widening clinical spectra of PTEN gene mutations have been acknowledged as the paradigm for the practice of clinical cancer genetics.
Dr. Eng grew up in Singapore and Bristol, UK and entered the University of Chicago at the age of 16. After completing an MD and PhD at its Pritzker School of Medicine, she specialized in internal medicine at Beth Israel Hospital, Boston and trained in medical oncology at Harvard’s Dana-Farber Cancer Institute. She was formally trained in clinical cancer genetics at the University of Cambridge and the Royal Marsden NHS Trust, UK, and in laboratory-based human cancer genetics by Bruce Ponder, MB, PhD at the University of Cambridge. At the end of 1995, Dr. Eng was recruited back to the Farber as Assistant Professor of Medicine, and in January, 1999 was recruited by The Ohio State University as Associate Professor of Medicine and Director of the Clinical Cancer Genetics Program. In 2001, she was honored with the conferment of the Davis Professorship and appointed Co-Director of the Division of Human Genetics in the Department of Internal Medicine. In 2002, she was promoted to Professor and Division Director, and was conferred the Klotz Endowed Chair. She moved to the Cleveland Clinic in Sept, 2005. Dr. Eng has published over 240 peer reviewed original papers in such journals as the New England Journal of Medicine, Lancet, JAMA, Nature Genetics, Nature and Molecular Cell. She was the North American Editor of the Journal of Medical Genetics from 1998 to 2005, is Senior Editor of Cancer Research and Associate Editor of the Journal of Clinical Endocrinology and Metabolism. Dr. Eng was recently elected to the Board of Directors of the American Society of Human Genetics.
Selected Peer Reviewed Publications (from >275):
Nelen MR, Padberg GW, Peeters EAJ, Lin A, van den Helm B, Frants RR, Coulon V, Goldstein AM, van Reen MMM, Easton DF, Eeles RA, Hodgson S, Mulvihill JJ, Murday VA, Tucker MA, Mariman ECM, Starink TM, Ponder BAJ, Ropers HH, Kremer H, Longy M, Eng C. Localization of the gene for Cowden disease to 10q22-23. Nature Genet 1996; 13:114-6.
Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, Ploos van Amstel HK, Lips CJM, Nishisho I, Takai S-I, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjöld M, Komminoth P, Hendy GN, Gharib H, Thibodeau SN, Lacroix A, Frilling A, Ponder BAJ, Mulligan LM. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET Mutation Consortium analysis. JAMA 1996; 276:1575-9.
Eng C. Seminars in Medicine of the Beth Israel Hospital, Boston: RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and Hirschsprung disease. N Engl J Med 1996; 335:943-51.
Liaw D, Marsh DJ, Li J, Dahia PLM, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C*, Parsons R*. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genet 1997; 16:64-7. (*Joint Senior Authors)
Marsh DJ, Dahia PLM, Zheng Z, Liaw D, Parsons R, Gorlin RJ, Eng C. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nature Genet 1997; 16:333-4.
Eng C, Vijg J. Genetic testing: the problems and the promise. Nature Biotechnol 1997; 15:422-6.
Eng C, Peacocke M. PTEN mutation analysis as a molecular diagnostic tool in the inherited hamartoma-cancer syndromes. Nature Genet 1998; 19:223.
Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Speigelman BM, Eng C. Loss-of-function mutations in PPARgamma associated with human colon cancer. Mol Cell 1999; 3:799-804.
Zhou XP, Hampel H, Thiele H, Gorlin RJ, Hennekam RCM, Parisi M, Winter RM, Eng C. Association of germline mutation in the PTEN tumour suppressor gene and a subset of Proteus sand Proteus-like syndromes. Lancet 2001; 358:210-1.
Neumann HPH, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehöfer C, Zerres K, Januszewicz A, Eng C. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346:1459-66.
Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nature Genet 2002; 32:355-7.
Ginn-Pease ME, Eng C. Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0G1 in MCF-7 cells. Cancer Res 2003; 63:282-6.
Eng C, Kiuru M, Fernandez MJ, Aaltonen LA. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nature Rev Cancer 2003; 3:193-202.
Zhou XP, Waite KA, Pilarski R, Hampel H, Fernandez MJ, Bos C, Dasouki M, Feldman GL, Greenberg L, Ivanovich J, Matloff E, Patterson A, Pierpont ME, Russo D, Nassif NT, Eng C. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet 2003; 73:404-11.
Waite KA, Eng C. From developmental disorder to cancer: it’s all in the BMP/TGFB family. Nature Rev Genet 2003; 4:763-73.
Neumann HPH, Pawlu C, Peçzkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley T, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C. Distinct clinical features characterize paraganglioma syndromes associated with SDHB and SDHD mutations. JAMA 2004; 292:943-51.
Fukino K, Shen L, Matsumoto S, Morrison CD, Mutter GL, Eng C. Combined total genome loss-of-heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets. Cancer Res 2004; 64:7231-6.
Chung JH, Ginn-Pease ME, Eng C. Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein. Cancer Res 2005; 65:4108-16.
Chung JH, Eng C. Nuclear-cytoplasmic partitioning of PTEN differentially regulates the cell cycle and apoptosis. Cancer Res 2005; 65:8096-8100.
Sweet K, Willis J, Zhou XP, Gallione C, Sawada T, Alhopuro P, Khoo SK, Patocs A, Martin C, Bridgeman S, Heinz J, Pilarski R, Lehtonen R, Prior TW, Frebourg T, Teh BT, Marchuk DA, Aaltonen LA, Eng C. Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA 2005; 294:2465-73.
Weber F, Shen L, Fukino K, Patocs A, Mutter GL, Caldes T, Eng C. Total genome analysis of BRCA1/2-related carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation. Am J Hum Genet 2006; 78:961-72.
Sarquis MS, Agrawal S, Shen L, Pilarski R, Zhou XP, Eng C. Distinct expression profiles of PTEN transcript and its splice variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. Am J Hum Genet 2006; 79:23-31.
Pezzolesi MG, Li Y, Zhou XP, Pilarski R, Shen L, Eng C. Mutation positive and mutation negative Cowden and Bannayan-Riley-Ruvalcaba syndrome patients associated with distinct haplotypes. Am J Hum Genet 2006; 79; 923-34.
Minaguchi T, Waite KA, Eng C. Nuclear import of PTEN is regulated by calcium through a tyrosil phosphorylation-independent conformational change. Cancer Res 2006; 66:11677-82.
Weber F, Xu Y, Zhang L, Patocs A, Shen L, Platzer P, Eng C. Microenvironmental genomic alterations and clinico-pathologic behavior in head and neck squamous cell carcinomas. JAMA 2007; 297:187-95.
Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, Yin Y. Essential role of PTEN in the maintenance of chromosome integrity. Cell 2007; 128:157-70.
Fukino K, Shen L, Patocs A, Mutter GL, Eng C. Genomic instability within tumor stroma and clinicopathologic characteristics of sporadic primary invasive breast carcinomas. JAMA 2007; 297:2103-11. (more)
Zbuk KM, Patocs A, Shealy A, Sylvester H, Miesfeldt S, Eng C. Germline
mutations in PTEN and SDHC in a woman with epithelial thyroid cancer and
carotid paranganglioma. Nature Clin Pract Oncol 2007; 4:608-12.
Neumann HPH, Vortmeyer A, Schmidt D, Werner M, Erlic Z, Cascon A, Bausch B,
Januzewicz A, Eng C. Evidence for MEN 2 in the original description of
pheochromocytoma. N Engl J Med 2007; 357:1311-5. (Link to Cleveland Plain Dealer article, September 28, 2007)
Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, Platzer P, Eng C.
Stromal TP53 mutation or 5-locus allelic imbalance and nodal metastases in
breast cancer. N Engl J Med 357:2543-51.
Assie G, LaFramboise T, Platzer P and Eng C. Frequency of germline genomic
homozygosity associated with cancer cases. JAMA 2008; 299:1437-1445.